Treatment and Management of Non-infectious Diseases
How do we treat non-infectious diseases once they develop? This lesson examines pharmacological, surgical, lifestyle and emerging treatments — evaluating their mechanisms, effectiveness, cost, and accessibility within the Australian healthcare system.
Practise this lesson
Four printable worksheets that build from the foundations up to exam-style questions — start at whatever level suits you.
Module 8 synthesis — how treatment connects to the disease mechanisms across the module
Marcus is 48 years old. He has just been told by his doctor that he has early-stage Type 2 diabetes. His fasting blood glucose is 8.2 mmol/L (normal: below 5.5 mmol/L). He has no other serious health conditions, but he is overweight and works long hours with little time to cook or exercise.
Before reading this lesson, consider:
Q1 — What treatment options might the doctor offer Marcus? List as many as you can think of — do not limit yourself to what you have studied.
Q2 — How would you decide which treatment is "best"? What factors matter beyond just whether the treatment works biologically?
Know
- The four main treatment categories: pharmacological, surgical, lifestyle, emerging (gene therapy)
- Specific examples: statins (CVD), metformin (T2D), chemotherapy and targeted therapy (cancer), CABG (CVD)
- The role of PBS and Medicare in treatment accessibility in Australia
Understand
- The mechanism by which each pharmacological treatment acts on its molecular target
- Why targeted therapy has fewer side effects than conventional chemotherapy
- Why lifestyle management is a treatment (not just prevention) for T2D and CVD
Can Do
- Evaluate the effectiveness, cost, and accessibility of two non-infectious disease treatments
- Explain why the "most effective" treatment is not always the "most appropriate" treatment for a given patient
- Describe gene therapy as an emerging (not yet widespread) treatment approach
Core Content
Pharmacological — Surgical — Lifestyle — Emerging
Treating a non-infectious disease does not mean reversing its cause — it means managing the disrupted mechanism, relieving symptoms, slowing progression, or replacing lost function.
The appropriate treatment depends on the disease type, its stage, the specific molecular disruption involved, and the individual patient's circumstances. In practice, most non-infectious diseases are managed with a combination of approaches rather than a single treatment.
Technology in disease management and monitoring
Health equity barriers to treatment access
Pharmacological
- Drugs targeting a specific molecule (enzyme, receptor, protein)
- Statins — block HMG-CoA reductase
- Metformin — reduces hepatic glucose output
- Chemotherapy — cytotoxic agents
- Targeted therapy — block cancer-specific proteins
Surgical
- Physically remove or repair diseased tissue
- CABG — bypass blocked coronary arteries
- Tumour excision — remove primary tumour
- Angioplasty + stenting — open blocked artery
- Bariatric surgery — T2D management in severe obesity
Lifestyle Management
- Dietary modification — reduce saturated fat, refined carbohydrates
- Physical activity — increases insulin sensitivity, reduces CVD risk
- Weight management — reduces insulin resistance
- Smoking cessation — reduces CVD and cancer risk further
- Cardiac rehabilitation programs post-event
Emerging — Gene Therapy
- Deliver functional gene copies using viral vectors
- CRISPR-Cas9 genome editing
- Currently experimental for most non-infectious diseases
- CF gene therapy in early clinical trials
- Full detail in L17
What to write in your book
- 4 categories: pharmacological (drugs), surgical (remove/repair), lifestyle (diet/exercise/weight), emerging (gene therapy — experimental).
- Treating ≠ reversing cause: manage mechanism, relieve symptoms, slow progression, or replace function.
- Most diseases managed with a combination of approaches.
- "Evaluate" = benefits AND limitations, not a list.
For an already-diagnosed patient with early-stage Type 2 diabetes, _____ management (diet, exercise, weight loss) is recommended first-line treatment — not just prevention.
Statins, metformin, chemotherapy and targeted therapy
Understanding the mechanism of a drug — not just its name — is required for HSC extended responses. Each drug works by targeting a specific molecular component of the disease pathway.
Disease: Cardiovascular disease (CVD) / atherosclerosis. Mechanism: Statins (e.g. atorvastatin, rosuvastatin) competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Reduced hepatic cholesterol production causes liver cells to upregulate LDL receptor expression, increasing uptake of circulating LDL-cholesterol. This lowers serum LDL levels, reducing atherosclerotic plaque formation and the risk of myocardial infarction and stroke. Statins also have anti-inflammatory effects on arterial walls. Limitations: Muscle pain (myopathy) in some patients; must be taken long-term; does not reverse existing plaques.
Disease: Type 2 diabetes. Mechanism: Metformin activates the enzyme AMPK (AMP-activated protein kinase) in the liver, which reduces gluconeogenesis (synthesis of glucose from non-carbohydrate sources) and reduces hepatic glucose output into the blood. It also improves insulin sensitivity in peripheral tissues by increasing GLUT4 transporter activity in muscle cells. The result is reduced fasting and post-meal blood glucose levels. Limitations: Gastrointestinal side effects (nausea, diarrhoea) initially; not suitable in severe kidney disease; does not restore lost beta-cell function.
Disease: Cancer (various types). Mechanism: Cytotoxic chemotherapy agents target rapidly dividing cells by interfering with DNA replication or cell division. Examples: cisplatin forms crosslinks in DNA, preventing replication; taxanes stabilise microtubules, blocking spindle formation in mitosis; antimetabolites (e.g. 5-fluorouracil) are incorporated into DNA/RNA in place of normal bases, disrupting synthesis. Limitations: Damages all rapidly dividing cells — including hair follicles, gut epithelium, and bone marrow — causing significant side effects (hair loss, nausea, immunosuppression). Resistance develops when cancer cells acquire mutations enabling drug efflux or DNA repair.
Disease: Specific cancer subtypes with identifiable molecular drivers. Mechanism: Targeted therapies block specific proteins that drive cancer cell division, rather than all dividing cells. Example: imatinib (Gleevec) is a tyrosine kinase inhibitor that specifically blocks BCR-ABL — the fusion oncoprotein produced by the Philadelphia chromosome translocation in chronic myeloid leukaemia (CML). Without BCR-ABL signalling, CML cells cannot divide. Another example: trastuzumab (Herceptin) binds to HER2 receptors on HER2-positive breast cancer cells, blocking growth signalling and triggering immune-mediated cell death. Advantage over chemotherapy: Because targeted therapies act on cancer-specific molecules, they produce fewer off-target side effects in normal tissue. Limitation: Only effective in tumours that express the specific molecular target; resistance develops.
What to write in your book
- Statins: inhibit HMG-CoA reductase → ↑LDL receptors → lower LDL.
- Metformin: activate AMPK → ↓gluconeogenesis (hepatic glucose output) + ↑GLUT4 sensitivity.
- Chemotherapy: cytotoxic — damages ALL rapidly dividing cells (hence side effects).
- Targeted therapy: blocks cancer-specific proteins (BCR-ABL, HER2) — fewer off-target effects but only if the target is present.
Metformin lowers blood glucose primarily by:
Coronary artery bypass graft (CABG) and tumour excision
Surgical treatments physically intervene in the disease process rather than targeting molecular mechanisms. They are generally reserved for cases where pharmacological or lifestyle management is insufficient, or where rapid intervention is required.
Coronary Artery Bypass Graft (CABG)
In advanced CVD, atherosclerotic plaques narrow or block coronary arteries, restricting blood flow to the myocardium. A CABG creates a new route for blood to bypass the blocked section by grafting a blood vessel (typically the saphenous vein from the leg, or the internal mammary artery) between the aorta and a point beyond the blockage.
Evaluation: CABG is highly effective for multi-vessel coronary artery disease where angioplasty is unsuitable. However, it is an open-heart procedure requiring general anaesthesia, carries significant surgical risk (infection, stroke, death), requires weeks of recovery, and costs approximately $30,000–$50,000 AUD. In Australia, Medicare covers most of this cost for eligible patients, making it accessible. Cardiac rehabilitation programs post-CABG significantly improve long-term outcomes.
Tumour Excision (Cancer Surgery)
Surgical removal of a primary tumour is the first-line treatment for many localised solid cancers (breast, bowel, melanoma). The goal is to remove the tumour with a clear margin of healthy tissue — ensuring no cancer cells remain at the edges (positive margins increase recurrence risk).
What to write in your book
- CABG: graft vessel (saphenous vein / internal mammary artery) bypasses blocked coronary segment → restores myocardial blood flow.
- CABG does NOT remove plaques → statins + lifestyle still needed post-surgery.
- Tumour excision: remove primary tumour with clear margins; curative only if localised (not metastasised).
- Early detection critical: stage I melanoma ~98% vs stage IV ~30–50% 5-year survival.
Surgical excision of the primary tumour cures cancer even after it has metastasised to distant organs.
Effective management of chronic non-infectious diseases often requires a combination of pharmacological, lifestyle, and monitoring interventions.
Once a patient starts medication for a chronic disease, lifestyle changes are no longer necessary for effective management.
Not just prevention — lifestyle modifies disease mechanisms in already-diagnosed patients
Lifestyle management is often presented as prevention, but for patients already diagnosed with Type 2 diabetes or CVD, it is also a primary treatment intervention — and in early-stage T2D, it can be sufficient to achieve remission without pharmacological treatment.
Type 2 Diabetes — Lifestyle as First-Line Treatment
In early-stage T2D (as in Marcus's case from Think First), the Australian Diabetes Society guidelines recommend lifestyle intervention as first-line treatment:
- Dietary modification: Reducing refined carbohydrate intake lowers post-meal blood glucose spikes. Reducing saturated fat decreases visceral fat, which drives insulin resistance. Increasing dietary fibre slows glucose absorption.
- Physical activity: Aerobic exercise increases GLUT4 transporter translocation to muscle cell membranes independently of insulin signalling — muscle cells can take up glucose without requiring insulin to function. This directly lowers blood glucose. Resistance training also increases muscle mass, expanding the body's glucose sink capacity.
- Weight reduction: Loss of 5–10% body weight significantly reduces visceral fat, which produces adipokines and free fatty acids that impair insulin receptor signalling. Substantial weight loss (>15%) can achieve sustained T2D remission in some patients.
CVD — Cardiac Rehabilitation
After a myocardial infarction (heart attack) or CABG, cardiac rehabilitation programs combine supervised exercise, dietary counselling, and psychological support. Structured cardiac rehabilitation reduces 30-day readmission rates by ~25% and significantly improves long-term survival. Lifestyle management post-CABG is essential because the surgery addresses the blockage but not the underlying atherosclerotic disease process.
What to write in your book
- Lifestyle is treatment (not just prevention) for already-diagnosed T2D/CVD.
- Diet (↓refined carbs, ↓saturated fat, ↑fibre); exercise (GLUT4 translocation — insulin-independent glucose uptake).
- Weight loss 5–10% ↓insulin resistance; >15% can achieve T2D remission.
- Cardiac rehabilitation post-MI/CABG reduces readmission ~25% and improves survival.
How does aerobic exercise lower blood glucose in a person with Type 2 diabetes?
The PBS, Medicare, and equity in treatment access
The HSC syllabus requires you to evaluate the effectiveness, cost, and accessibility of treatments for at least two non-infectious diseases. "Evaluate" means providing a balanced judgement — acknowledging strengths and limitations — not simply listing features.
| Treatment | Disease | Effectiveness | Cost (AUD) | Accessibility |
|---|---|---|---|---|
| Statins | CVD | Reduces major cardiovascular events by ~25–35% in high-risk individuals; highly evidence-based (large RCTs) | ~$5–$40/month on PBS; low cost | High — PBS-listed, GP prescription, widely available |
| Metformin | Type 2 diabetes | Reduces HbA1c by 1–2%; slows progression; evidence-based first-line drug; does not restore beta-cell function | ~$6/month on PBS; very low cost | Very high — PBS-listed, cheap, tolerated by most patients |
| CABG | CVD (multi-vessel) | Highly effective for severe multi-vessel disease; superior to medical management alone in suitable patients; improves survival and quality of life | $30,000–$50,000; covered by Medicare for eligible patients | Moderate — requires referral, specialist, hospital, recovery time; rural access limited |
| Targeted therapy (imatinib) | CML (cancer) | Excellent — 10-year survival in CML exceeds 80%; dramatically superior to previous chemotherapy regimens | ~$40,000/year without subsidy; ~$40/month on PBS for eligible patients | PBS-listed in Australia — very high accessibility nationally; globally, cost is a major equity barrier |
| Lifestyle management | T2D / CVD | Can achieve T2D remission in early-stage disease (weight loss >15%); reduces CVD recurrence; highly effective when sustained | Very low direct cost; time and behavioural demand high | Variable — depends on food security, time, access to safe exercise, support services; socioeconomic barriers exist |
| Gene therapy | CF (experimental) | Promising early trials; not yet approved as standard treatment; long-term efficacy unknown | Extremely high (>$1 million per treatment where approved); not yet PBS-listed for most conditions | Very low — limited to clinical trial sites; not routinely available |
The Role of PBS and Medicare in Australia
The Pharmaceutical Benefits Scheme (PBS) subsidises approved medicines, meaning patients pay a co-payment (currently ~$7.70 for concession holders, ~$31.60 general, as of 2024) rather than the full market price. Without PBS listing, imatinib would cost ~$40,000 per year — placing it beyond reach for most Australians. Medicare covers hospital care including CABG surgery and specialist consultations, substantially reducing the financial barrier to surgical intervention.
However, accessibility is not purely financial. Geographic barriers (rural and remote Australians have reduced access to specialist surgeons and cardiac rehabilitation programs), health literacy, and socioeconomic determinants of health create inequality in treatment uptake even when treatments are theoretically subsidised.
What to write in your book
- Evaluate = effectiveness + cost + accessibility (balanced judgement, not a list).
- PBS subsidises medicines (imatinib ~$40,000/yr → ~$40/month); Medicare covers hospital care (CABG).
- Accessibility is not only financial — geography, health literacy, socioeconomic factors matter.
- Rural access remains a significant equity gap.
The most biologically effective treatment is always the most appropriate treatment for every patient.
Patient compliance with treatment regimens is a major challenge in managing chronic diseases.
Chronic disease management focuses only on curing the disease completely rather than controlling symptoms.
Overview only — full analysis in L17
Gene therapy aims to treat disease at its genetic cause, rather than managing its downstream consequences. Two main approaches are relevant to non-infectious disease:
- Gene replacement: A functional copy of a mutated gene is delivered into target cells using a viral vector (typically an adeno-associated virus, AAV). Example: trials delivering functional CFTR gene copies to lung epithelial cells in cystic fibrosis patients. The vector carries the gene into the cell nucleus where it is expressed, producing functional CFTR protein.
- Genome editing (CRISPR-Cas9): The Cas9 endonuclease is guided to a specific DNA sequence by a guide RNA, where it makes a precise cut. The cell's repair machinery then inserts a corrected sequence. This has been used experimentally to correct BRCA1 mutations in cell cultures and has entered clinical trials for some cancers and genetic blood disorders (sickle cell disease, beta-thalassaemia).
The key limitation of gene therapy is delivery — getting the functional gene or editing machinery to the correct cells in sufficient quantities without triggering an immune response. Immune reactions to viral vectors have caused serious adverse events in early trials. Off-target genome editing effects are also a safety concern for CRISPR-based approaches.
What to write in your book
- Gene replacement: deliver functional gene via viral vector (AAV) → expressed in target cells (e.g. CFTR for CF).
- CRISPR-Cas9: guide RNA directs Cas9 to cut DNA → repair inserts corrected sequence.
- Still EXPERIMENTAL for most non-infectious diseases — qualify in exam answers.
- Key limitation = delivery (immune reactions to viral vectors; off-target editing).
Returning to Marcus from Think First: with early-stage T2D (HbA1c likely 6.5–8%), Australian Diabetes Society guidelines recommend starting with lifestyle intervention — structured dietary counselling (reduce refined carbohydrates, increase fibre and protein) and at least 150 minutes of moderate physical activity per week — for 3–6 months before considering pharmacological treatment.
If lifestyle modification alone does not achieve target HbA1c (below 7.0% for most patients), metformin is added as first-line pharmacological therapy. On the PBS, this costs Marcus approximately $6–$31 per month depending on his concession status. If he works long hours with limited time to cook or exercise, the lifestyle component may be the most challenging to sustain — which is why the Australian healthcare system funds diabetes education nurses and dietitian referrals through Medicare's Chronic Disease Management Plan.
The "best" treatment for Marcus is not solely the most biologically effective — it must be practical, sustainable, affordable, and suited to his specific circumstances.
4 Treatment Categories
- Pharmacological: drugs targeting specific molecules
- Surgical: physical removal or repair of diseased tissue
- Lifestyle: diet, exercise, weight management
- Emerging: gene therapy (experimental)
Drug Mechanisms
- Statins: inhibit HMG-CoA reductase → lower LDL
- Metformin: activate AMPK → reduce hepatic glucose output
- Chemotherapy: cytotoxic, damages all dividing cells
- Targeted therapy: blocks cancer-specific proteins (BCR-ABL, HER2)
Evaluation Criteria
- Effectiveness: evidence base, degree of symptom reduction
- Cost: before and after PBS/Medicare subsidy
- Accessibility: geographic, financial, time, health literacy barriers
- Side effects and long-term suitability
Australian Context
- PBS subsidises approved medicines (statins, metformin, imatinib)
- Medicare covers hospital care including CABG
- Chronic Disease Management Plan: allied health referrals
- Rural access remains a significant equity gap
A fresh set drawn from this lesson's question bank — feedback shown immediately. +5 XP per correct · +25 XP all correct
Pick your answer, then rate your confidence — that tells the system what to drill next.
ApplyBand 4(4 marks) 1. Explain the mechanism by which metformin reduces blood glucose levels in a patient with Type 2 diabetes. Identify the specific enzyme activated by metformin, describe two cellular processes that are affected, and explain why metformin is described as improving insulin sensitivity rather than replacing insulin.
AnalyseBand 4–5(5 marks) 2. Compare conventional chemotherapy with targeted therapy (such as imatinib for CML) in terms of: (a) mechanism of action, (b) specificity for cancer cells, and (c) side effect profile. Conclude with an explanation of why targeted therapy is not suitable for all cancer patients.
EvaluateBand 5–6(6 marks) 3. "The most biologically effective treatment for a non-infectious disease is always the most appropriate treatment for a patient." Evaluate this statement using examples from two different non-infectious diseases and their treatment options. Refer to effectiveness, cost, accessibility, and patient-specific factors.
Show all answers
Multiple choice
MC answers and full explanations are shown inline as you complete each question. Use the retry button to attempt a fresh set from the lesson bank.
Activity 1 — Match Treatments to Mechanisms
1. Atorvastatin. Category: pharmacological. Disease: CVD/atherosclerosis. Mechanism: competitively inhibits HMG-CoA reductase (rate-limiting enzyme of hepatic cholesterol synthesis) → reduced intracellular cholesterol → liver upregulates LDL receptors → increased clearance of circulating LDL → lower serum LDL → less lipid substrate for plaque formation → slower disease progression and reduced MI/stroke risk.
2. Structured diet + exercise program for T2D. Category: lifestyle management. Why treatment not just prevention: the patient already has T2D, so the program targets the existing disease mechanisms (insulin resistance, hyperglycaemia). Exercise mechanism: aerobic exercise activates AMPK in muscle → GLUT4 translocation to the membrane independently of insulin → muscle takes up glucose during exercise without insulin → lowers blood glucose. Resistance training increases muscle mass (glucose sink); weight loss reduces visceral fat → less adipokine-driven insulin resistance.
3. Imatinib for CML. Category: pharmacological — targeted therapy. Why more appropriate than chemotherapy: BCR-ABL is expressed only by CML cells (Philadelphia chromosome translocation); normal cells lack it. Imatinib binds the ATP-binding site of BCR-ABL, blocking phosphorylation of downstream proliferation signals — so it spares normal bone marrow, gut, and follicle cells that chemotherapy damages. 10-year CML survival exceeds 80% with imatinib.
4. CABG + post-surgical statins/lifestyle. Category: surgical. CABG grafts a vessel (saphenous vein / internal mammary artery) from the aorta to a point beyond the blockage, restoring myocardial blood flow, relieving angina and reducing MI risk. Statins + lifestyle still needed because CABG reroutes blood but does NOT remove plaques or correct the lipid metabolism abnormality; without them, atherosclerosis progresses in other arteries and the graft itself.
Activity 2 — Evaluating Treatment Options
1. T2D patient (BMI 38, HbA1c 9.5% on metformin). GLP-1 agonist (e.g. semaglutide): stimulates meal-related insulin, suppresses glucagon, slows gastric emptying, promotes satiety → lowers HbA1c and produces weight loss; limitation: cost without full subsidy, ongoing use. Bariatric surgery: most effective long-term — >50% T2D remission at 5 years in BMI ≥35 due to major weight loss and gut hormone changes; limitation: major surgical risk, lifelong nutritional supplementation, not for high surgical-risk patients. Intensified lifestyle: effective if sustained (15% loss can achieve remission); limitation: hard to maintain with HbA1c already 9.5% without intensive support. Conclusion: for BMI 38 inadequately controlled on metformin, the strongest evidence supports adding a GLP-1 agonist plus bariatric surgery assessment (combining glucose control with addressing the obesity root driver).
2. Statins vs CABG for CVD. (a) Statins inhibit HMG-CoA reductase → lower LDL → slow plaque formation; CABG bypasses blocked arteries → restores myocardial blood flow. (b) Statins effective for primary and secondary prevention across all groups; CABG superior for severe multi-vessel disease. (c) Statins ~$5–40/month PBS, GP-prescribed, accessible (incl. rural); CABG $30,000–50,000 (Medicare-covered) but needs referral, hospital, recovery, limited rural access. (d) Statins: lifelong use, myopathy, don't restore flow; CABG: surgical risk (~1–2% mortality), recovery, graft failure over time, doesn't treat underlying disease. Conclusion: statins are first-line and lifelong for all CVD patients; CABG is reserved for severe multi-vessel disease; they are complementary (CABG patients require statins post-surgery).
Short Answer Model Answers
SA1 (4 marks): Enzyme: AMPK (AMP-activated protein kinase) in hepatocytes [0.5]. Process 1: AMPK activation inhibits gluconeogenic enzymes (PEPCK, G6Pase), reducing glucose synthesis from non-carbohydrate precursors → lower hepatic glucose output into the blood → reduced fasting glucose [1]. Process 2: metformin increases GLUT4 transporter translocation to the membranes of muscle/adipose cells, improving glucose uptake into peripheral tissues independently of insulin receptor signalling → increased insulin sensitivity [1]. Why "improves insulin sensitivity" not "replaces insulin": metformin supplies no exogenous insulin, does not stimulate beta-cell secretion, and does not mimic insulin at its receptor — it makes existing cells respond more effectively to the insulin already present (downstream signalling and transporters). Insulin is still required; metformin reduces the amount needed [1.5].
SA2 (5 marks): (a) Chemotherapy (e.g. cisplatin crosslinks DNA; taxanes stabilise microtubules blocking the spindle) affects all rapidly dividing cells; imatinib binds the ATP-binding site of BCR-ABL kinase, blocking phosphorylation of downstream growth-signalling proteins so CML cells cannot divide [1.5]. (b) Chemotherapy has low specificity (any dividing cell — bone marrow, gut, follicles); imatinib has high specificity (BCR-ABL only in CML cells carrying the Philadelphia chromosome) [1.5]. (c) Chemotherapy causes immunosuppression, mucositis, alopecia, severe nausea; imatinib causes mild nausea, oedema and fatigue, with rare severe marrow suppression [1]. Why not suitable for all cancers: targeted therapy needs a specific, identifiable molecular driver that is expressed in the patient's tumour and pharmacologically blockable. Cancers lacking the relevant target (no BCR-ABL, HER2 overexpression, or BRAF V600E) have nothing for the drug to act on; many cancers have heterogeneous mutation profiles without a single dominant targetable driver [1].
SA3 (6 marks): The statement is incorrect — biological effectiveness is necessary but insufficient; appropriateness also requires cost, accessibility, side effects and patient-specific factors [0.5]. Example 1 — CVD: CABG is the most biologically effective intervention for severe multi-vessel disease, but for an 80-year-old with comorbidities the surgical risk (mortality ~1–2%, stroke, infection) outweighs the benefit, making statins + lifestyle more appropriate; for a rural patient, limited surgical access reduces feasibility even when indicated [1.5]. Example 2 — T2D: bariatric surgery produces the greatest long-term effect (>50% remission in severe obesity), but for early-stage T2D (HbA1c 8.2%) the risk-benefit favours lifestyle + metformin (~$6/month PBS) — equally effective at this stage with far lower risk and cost [1.5]. Effectiveness alone does not determine appropriateness because a treatment that is unavailable, unaffordable, or unsafe for a given patient cannot be administered; one the patient can access, afford and adhere to produces better real-world outcomes [1.5]. Conclusion: the most appropriate treatment is the most effective option that can be safely administered, accessed and maintained by the specific patient — integrating effectiveness with cost, accessibility, risk and patient circumstances [1].
Five timed questions on treatment categories, drug mechanisms and evaluating effectiveness/cost/accessibility. Beat the boss to bank a tier — gold (perfect + fast), silver (80%+), or bronze (cleared).
⚔ Enter the arenaAnswer questions on pharmacological, surgical, lifestyle and emerging treatments — and how Australia funds them. Pool: lessons 1–15.
Return to your Think First responses about Marcus's treatment options.
- Q1 — Treatment options: Can you now name specific pharmacological agents with mechanisms? Metformin (AMPK activation → reduced hepatic glucose output), lifestyle management (GLUT4 translocation via exercise, weight loss → reduced insulin resistance). Gene therapy is experimental only — not yet available for T2D.
- Q2 — What makes treatment "best"? A framework: effectiveness (mechanism and evidence), cost (PBS co-payment), accessibility (time, rural access, health literacy), and patient-specific factors (Marcus's long hours make lifestyle compliance challenging). The best treatment is the one Marcus can actually sustain.
- Write Marcus's complete treatment plan from memory: starting with lifestyle intervention, when metformin would be added, what monitoring is needed (HbA1c every 3–6 months), and what would indicate escalation to a second agent.